Shufeng Zhou

Summary

Affiliation: University of Auckland
Country: New Zealand

Publications

  1. ncbi request reprint Determination of the covalent adducts of the novel anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid in biological samples by high-performance liquid chromatography
    S Zhou
    Department of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, University of Auckland, New Zealand
    J Chromatogr B Biomed Sci Appl 757:343-8. 2001
  2. ncbi request reprint Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation
    Shufeng Zhou
    Division of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
    Drug Metab Rev 34:751-90. 2002
  3. ncbi request reprint Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid
    Shufeng Zhou
    Division of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland, New Zealand
    Biochem Pharmacol 65:109-20. 2003
  4. ncbi request reprint 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy
    Shufeng Zhou
    Division of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, University ofAuckland, New Zealand
    Invest New Drugs 20:281-95. 2002
  5. ncbi request reprint Non-specific binding of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in liver microsomes from various species
    Shufeng Zhou
    Division of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, The University of Auckland, New Zealand
    J Pharm Pharmacol 54:997-1003. 2002
  6. ncbi request reprint Strain differences in the liver microsomal metabolism of the experimental anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in mice
    Shufeng Zhou
    Division of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
    J Chromatogr B Analyt Technol Biomed Life Sci 776:231-6. 2002
  7. ncbi request reprint Thalidomide in cancer treatment: a potential role in the elderly?
    Shufeng Zhou
    Division of Pharmacology and Clinical Pharmacology, School of Medicine, The University of Auckland, Auckland, New Zealand
    Drugs Aging 19:85-100. 2002
  8. ncbi request reprint Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo
    S F Zhou
    Division of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, University of Auckland, New Zealand
    Xenobiotica 32:87-107. 2002
  9. ncbi request reprint High-throughput screening of potential inhibitors for the metabolism of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid
    Shufeng Zho
    Division of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, The University of Auckland, New Zealand
    J Chromatogr B Analyt Technol Biomed Life Sci 767:19-26. 2002
  10. ncbi request reprint Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
    Shufeng Zhou
    Division of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Cancer Chemother Pharmacol 49:126-32. 2002

Collaborators

Detail Information

Publications22

  1. ncbi request reprint Determination of the covalent adducts of the novel anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid in biological samples by high-performance liquid chromatography
    S Zhou
    Department of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, University of Auckland, New Zealand
    J Chromatogr B Biomed Sci Appl 757:343-8. 2001
    ..The limit of detection for the covalent adduct in human plasma or HSA is 0.20 microM. The methods presented good accuracy, precision and sensitivity for use in the preclinical and clinical studies...
  2. ncbi request reprint Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation
    Shufeng Zhou
    Division of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
    Drug Metab Rev 34:751-90. 2002
    ..These data indicate that preclincial pharmacokinetic studies using both in vitro and in vivo models play an important but different role in predicting pharmacokinetics and drug interactions in patients...
  3. ncbi request reprint Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid
    Shufeng Zhou
    Division of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland, New Zealand
    Biochem Pharmacol 65:109-20. 2003
    ..However, clinical studies are important to verify the conclusions drawn from in vitro data...
  4. ncbi request reprint 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy
    Shufeng Zhou
    Division of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, University ofAuckland, New Zealand
    Invest New Drugs 20:281-95. 2002
    ..Further studies are required to explore the molecular targets of DMXAA and mechanisms for the interactions with other drugs co-administered during combination treatment, which may allow for the optimisation of DMXAA-based chemotherapy...
  5. ncbi request reprint Non-specific binding of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in liver microsomes from various species
    Shufeng Zhou
    Division of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, The University of Auckland, New Zealand
    J Pharm Pharmacol 54:997-1003. 2002
    ..These results indicate that the non-specific binding of DMXAA to microsomes is insignificant and has little impact on the enzyme kinetic estimation in-vitro...
  6. ncbi request reprint Strain differences in the liver microsomal metabolism of the experimental anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in mice
    Shufeng Zhou
    Division of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
    J Chromatogr B Analyt Technol Biomed Life Sci 776:231-6. 2002
    ....
  7. ncbi request reprint Thalidomide in cancer treatment: a potential role in the elderly?
    Shufeng Zhou
    Division of Pharmacology and Clinical Pharmacology, School of Medicine, The University of Auckland, Auckland, New Zealand
    Drugs Aging 19:85-100. 2002
    ..The exact role of thalidomide in the treatment of cancer and cancer cachexia in the elderly remains to be elucidated. However, it may have some value as part of a multimodality anticancer therapy, rather than as a single agent...
  8. ncbi request reprint Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo
    S F Zhou
    Division of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, University of Auckland, New Zealand
    Xenobiotica 32:87-107. 2002
    ..6. The results indicate that animal models may have a limited role in the extrapolation to patients of drug interactions with agents such as DMXAA that have immunomodulating activity that may vary widely between species...
  9. ncbi request reprint High-throughput screening of potential inhibitors for the metabolism of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid
    Shufeng Zho
    Division of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, The University of Auckland, New Zealand
    J Chromatogr B Analyt Technol Biomed Life Sci 767:19-26. 2002
    ..This study has been completed using a strategy for rapid HPLC analysis and thus provided early access to detailed information for potential inhibitors of DMXAA metabolism and allows for further DMXAA-drug interaction studies...
  10. ncbi request reprint Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
    Shufeng Zhou
    Division of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Cancer Chemother Pharmacol 49:126-32. 2002
    ..In addition, the in vitro metabolism and plasma protein binding of DMXAA in male and female mice, rats and humans were investigated...
  11. ncbi request reprint Determination of unbound concentration of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in human plasma by ultrafiltration followed by high-performance liquid chromatography with fluorimetric detection
    S Zhou
    Department of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, University of Auckland, New Zealand
    J Chromatogr B Biomed Sci Appl 757:359-63. 2001
    ..The difference between the theoretical and calculated concentration and the relative standard deviation were less than 10% at all quality control (QC) concentrations. The HPLC method has been used for the analysis of preclinical studies...
  12. ncbi request reprint Antitumor activity and underlying mechanisms of ganopoly, the refined polysaccharides extracted from Ganoderma lucidum, in mice
    Yihuai Gao
    Institute of Food, Nutrition and Human Health, Massey University, Auckland, New Zealand
    Immunol Invest 34:171-98. 2005
    ..The overall findings indicated that Ganopoly had antitumor activity with a broad spectrum of immuno-modulating activities and may represent a novel promising immunotherapeutic agent in cancer treatment...
  13. ncbi request reprint Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid
    Shufeng Zhou
    Division of Pharmacology and Clinical Pharmacology, The University of Auckland, Private Bag 92019, Auckland, New Zealand
    Biochem Pharmacol 65:1853-65. 2003
    ..Further study is needed to examine the genotype-phenotype relationship, and the result, together with therapeutic drug monitoring may provide a useful strategy for optimizing DMXAA treatment...
  14. ncbi request reprint Ganoderma lucidum polysaccharide fractions accelerate healing of acetic acid-induced ulcers in rats
    Yihuai Gao
    Institute of Food, Nutrition and Human Health, Massey University, Auckland, New Zealand
    J Med Food 7:417-21. 2004
    ..These results indicates that G. lucidum PS is an active component with healing efficacy on acetic acid-induced ulcers in the rat, which may represent a useful herbal preparation for the prevention and treatment of peptic ulcers...
  15. ncbi request reprint A randomized, double-blind and placebo-controlled study of a Ganoderma lucidum polysaccharide extract in neurasthenia
    Wenbo Tang
    New Zealand Institute of Natural Medicine Research, Auckland, New Zealand
    J Med Food 8:53-8. 2005
    ..51; df = 1; P = .002). Ganopoly was well tolerated in the study patients. These findings indicated that Ganopoly was significantly superior to placebo with respect to the clinical improvement of symptoms in neurasthenia...
  16. ncbi request reprint Determination of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide in Caco-2 monolayers by liquid chromatography with fluorescence detection: application to transport studies
    Shufeng Zhou
    Department of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland, New Zealand
    J Chromatogr B Analyt Technol Biomed Life Sci 809:87-97. 2004
    ..DMXAA across Caco-2 monolayers was through a passive transcellular process, whereas the transport of DMXAA-G was mediated by MRP1/2...
  17. ncbi request reprint Transport of thalidomide by the human intestinal caco-2 monolayers
    Shufeng Zhou
    Department of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
    Eur J Drug Metab Pharmacokinet 30:49-61. 2005
    ..These results indicated that thalidomide was rapidly transported by Caco-2 monolayers, and this might involve a saturable energy-dependent transporter...
  18. ncbi request reprint Inhibition of human CYP1A2 oxidation of 5,6-dimethyl-xanthenone-4-acetic acid by acridines: a molecular modelling study
    James W Paxton
    Department of Pharmacology and Clinical Pharmacology, Auckland Cancer Society Research Centre, The University of Auckland, Auckland, New Zealand
    Clin Exp Pharmacol Physiol 32:633-9. 2005
    ....
  19. ncbi request reprint 6-methylhydroxylation of the anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by flavin-containing monooxygenase 3
    Shufeng Zhou
    Division of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand
    Eur J Drug Metab Pharmacokinet 27:179-83. 2002
    ..The results of this study indicate that human FMO3 has the capacity to form 6-OH-MXAA, but plays a lesser important role for this reaction than CYP1A2 that has been demonstrated to catalyse 6-OH-MXAA formation...
  20. ncbi request reprint Determination of thalidomide in transport buffer for Caco-2 cell monolayers by high-performance liquid chromatography with ultraviolet detection
    Shufeng Zhou
    Division of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, The University of Auckland, 85 Park Road, Grafton Private Bag 92019, New Zealand
    J Chromatogr B Analyt Technol Biomed Life Sci 785:165-73. 2003
    ..These results indicate that the transport of thalidomide by Caco-2 monolayers was rapid, which might involve an energy-dependent mechanism...
  21. ncbi request reprint Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans
    S F Zhou
    Department of Pharmacology and Clinical Pharmacology, University of Auckland, New Zealand
    Xenobiotica 31:277-93. 2001
    ..The reactive properties of DMXAA-G may have important implications for the pharmacokinetics, pharmacodynamics and toxicity of DMXAA...
  22. ncbi request reprint Mechanism of the antiulcerogenic effect of Ganoderma lucidum polysaccharides on indomethacin-induced lesions in the rat
    Yihuai Gao
    New Zealand Institute of Natural Medicines, Auckland, New Zealand
    Life Sci 72:731-45. 2002
    ..05-1.0 mg/ml increased the c-Myc protein expression. These findings indicated that GLPS produced a mucosal healing effect in the rat model, perhaps due partly to the suppression of TNF-alpha and induction of c-myc and ODC gene...